INDs submitted to Center for Drug Evaluation and Research (CDER)

Options include:

  1. Mail to CDER (Currently not being accepted by CDER):
    • Mail application in triplicates (one original and two copies) or an e-copy (CD, flash drive, etc.) plus a paper, signed cover letter to:
      • Food and Drug Administration
        Center for Drug Evaluation and Research
        Central Document Room
        5901-B Ammendale Rd.
        Beltsville, Md. 20705-1266
  2. Submit through CDER NextGen Portal
    • Everything submitted through this portal must be in a PDF format for it to be accepted.  When it has successfully been submitted, you will receive a confirmation email.  This confirmation email doesn’t mean that your submission has been reviewed and is safe to proceed; it just means that your submission has been received by CDER.
    • Reference guide to create an account and logging into to CDER NextGen Portal
    • FAQs for CDER NextGen Portal
  3. FDA Electronic Submissions Gateway (please see below on instructions how to use)

Single Patient INDs submitted to CDER or CBER (Alternative to the above options)

  • Reagan-Udall Foundation (RUF) - An alternative submission process for single patient IND initial and follow up submissions. This website should not be used for emergency use IND requests. If the IND is submitted through RUF, it should not be submitted through the FDA normal submission channels (ex: CDER NextGen Portal).

Contact us

Lauren Wallace, M.S., RAC-Drugs

Director of clinical research regulatory affairs
Division of Strategy and Regulatory Affairs

Portrait placeholder

Elizabeth Kissell, MPH, CCRP

Clinical research monitor/FDA program administrator
Division of Strategy and Regulatory Affairs

Elizabeth Kissell headshot

Regulatory affairs


Division of Strategy and Regulatory Affairs

Portrait placeholder